• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Live Link
    • Truveta Studio
  • Genomics
  • Solutions
    • Medical devices
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • News
    • Careers

Get started
Sign in
Close
The FDA just changed the rules. Here’s what we owe patients.

The FDA just changed the rules. Here’s what we owe patients.

by Johnathan Lancaster, MD, PhD | Feb 24, 2026 | News

Last week, Vinay Prasad and Martin Makary published a landmark piece in the New England Journal of Medicine announcing that the FDA’s new default standard for marketing authorization will be one adequate and well-controlled clinical trial, supported by confirmatory...
With the FDA ending the two-trial default, the era of intelligent evidence has begun

With the FDA ending the two-trial default, the era of intelligent evidence has begun

by Terry Myerson, CEO | Feb 23, 2026 | News

When the Supreme Court changes a legal standard, the system adjusts. When the FDA changes a regulatory default, the drug development ecosystem recalibrates. Last week’s FDA decision to make one adequate and well-controlled trial the default, supported by confirmatory...
Truveta Live Link: Enabling more complete real-world evidence and prospective research

Truveta Live Link: Enabling more complete real-world evidence and prospective research

by Truveta staff | Feb 18, 2026 | News

Real-world evidence is critical for understanding how therapies perform beyond controlled clinical trials. Yet many life sciences organizations rely on fragmented proprietary data that lack the longitudinal clinical context needed to support regulatory, payer, and...
Truveta experts: Antidepressant treatment duration trends

Truveta experts: Antidepressant treatment duration trends

by Truveta staff | Feb 18, 2026 | Research

In this Truveta experts analysis, Amy Sullivan, MS examines real-world antidepressant prescribing episodes using linked electronic health record (EHR) and closed claims data from more than 14.5 million individuals. The analysis characterizes the duration, recurrence,...
Real-world evidence on heart failure from GLP-1 and advanced CKD populations

Real-world evidence on heart failure from GLP-1 and advanced CKD populations

by Truveta staff | Feb 12, 2026 | Research

Two new peer-reviewed studies published in the Journal of Cardiac Failure showcase how clinicians and researchers at Baylor Scott & White Research Institute, working in collaboration with Baylor Scott & White Health and Stony Brook Medicine investigators, are...
Early uptake of oral semaglutide for obesity (Wegovy pill) following FDA approval

Early uptake of oral semaglutide for obesity (Wegovy pill) following FDA approval

by Truveta Research | Feb 11, 2026 | Featured research, Research

A large proportion of early users (36.1%) of oral semaglutide (Wegovy pill) had no prior evidence of GLP-1-based medication use, suggesting rapid uptake among patients new to taking GLP-1 medications. Among patients who previously used a GLP-1-based medication, most...
Use of GLP-1 RAs following label expansion for patients with CVD and overweight or obesity

Use of GLP-1 RAs following label expansion for patients with CVD and overweight or obesity

by Truveta Research | Feb 10, 2026 | Research

Authors: Duy Do, PhD⊕Truveta, Inc, Bellevue, WA, Karthik Murugiah, MD ⊕Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT,...
Hematologic oncology at scale: From population insight to patient-level risk signals

Hematologic oncology at scale: From population insight to patient-level risk signals

by Truveta staff | Feb 5, 2026 | Research

Hematologic oncology is at an inflection point. Over the past decade, innovation in blood cancers has accelerated dramatically. Breakthroughs like CAR-T and next-generation immunotherapies have redefined what’s possible for patients with blood cancers, turning...
Evaluating changes in lidocaine and opioid administration on the day of IUD insertion, 2018-2025

Evaluating changes in lidocaine and opioid administration on the day of IUD insertion, 2018-2025

by Truveta Research | Feb 2, 2026 | Research

Authors: Nina B. Masters, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Karen G. Farrar, PhD ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc,...
Truveta experts: What adolescent sleep disorders reveal about mental health trends

Truveta experts: What adolescent sleep disorders reveal about mental health trends

by Truveta staff | Feb 2, 2026 | Research

In this Truveta experts analysis, Karen Gilbert Farrar, PhD examines the relationship between sleep disorders and mental health conditions among adolescents using Truveta’s de-identified electronic health record (EHR) data. The analysis focuses on patients ages 12–17...
Real-world survival outcomes after cardiac contractility modulation: New research from Impulse Dynamics

Real-world survival outcomes after cardiac contractility modulation: New research from Impulse Dynamics

by Truveta staff | Jan 29, 2026 | Research

New peer-reviewed research published in the Journal of Cardiac Failure offers promising real-world evidence on long-term survival after cardiac contractility modulation (CCM), a device-based therapy for patients with symptomatic heart failure who are not candidates...
Clinical trials: Introducing real-time trial design, optimization, and evidence generation

Clinical trials: Introducing real-time trial design, optimization, and evidence generation

by Truveta News | Jan 27, 2026 | News

Clinical trials remain one of the most resource-intensive stages of drug development. Slow enrollment, protocol amendments, zero-enrollment sites, and incomplete real-world evidence can delay timelines and increase cost—ultimately slowing access to life-changing...
« Older Entries
Next Entries »

Share this


Recent posts

  • Estrogen-based hormone replacement therapy use is rising
  • Four real-world insights reshaping urology: New evidence from Boston Scientific
  • University of Michigan study sets a new benchmark for cervical cancer screening in the US

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Research

Resources

Blog

News

Careers

Privacy notice

Contact us

© Truveta 2026

Our website uses cookies to ensure you have the best experience.